Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E2086
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
E2086 is an orally bioavailable, selective and potent small molecule agonist of the orexin receptor type 2 (orexin-2 receptor), developed by Eisai for the treatment of narcolepsy type 1. The drug is designed to compensate for orexin loss in patients with narcolepsy, aiming to increase wakefulness and reduce cataplexy episodes. Nonclinical studies have shown that E2086 increases time spent awake and reduces cataplexy-like episodes in animal models. As of mid-2024, it is in Phase I clinical trials for narcolepsy type 1[1][3][4][7].
- Other names
- E 2086E2086E-2086
02
Targets
HCRTR2 (Orexin/hypocretin receptor type 2)
Beyond the preview
Go deeper on E2086.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E2086.